Clinical trial
A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)
NCT00525447 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2007
- Completion date
- February 28, 2010
- Enrollment
- 36 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.